Heart failure with preserved ejection fraction in hypertension

Current Opinion in Cardiology

Volumn 31, Issue 4, 2016, Pages 410-416

  Teo, Loon Yee Louis ^a   Chan, Laura Lihua ^a   Lam, Carolyn Su Ping ^a,b  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Heart failure with preserved ejection fraction; Hypertension; Pathogenesis; Pathophysiology

Indexed keywords

COLLAGEN; CONNECTIN; CYCLIC GMP;

DIASTOLIC DYSFUNCTION; DISEASE COURSE; FIBROSIS; HEART DILATATION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE EJECTION; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIA; MYOCARDIAL DISEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; CARDIAC MUSCLE; HEART FAILURE; HEART STROKE VOLUME; PHYSIOLOGY;

HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; STROKE VOLUME;

EID: 84963691781     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000292     Document Type: Review

References (46)

1. Kannel WB, Castelli WP, McNamara PM, et al. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med 1972; 287:781-787.
2. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009; 119:3070-3077.
3. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13:18-28.
4. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147-e239.
5. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep 2013; 10:401-410.
6. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992; 327:998-1008.
7. Lam CS, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricularvascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007; 115:1982-1990.
8. Heinzel FR, Hohendanner F, Jin G, et al. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J Appl Physiol 2015; 119:1233-1242. This review outlines the experimental and clinical evidence that links left ventricular (LV) hypertrophy to diastolic dysfunction and HFpEF. The role of LV hypertrophy as a diagnostic and prognostic marker in HFpEF is also discussed.
9. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32:670-679.
10. Kovács Á, Papp Z, Nagy L. Causes and pathophysiology of heart failure with preserved ejection fraction. Heart Fail Clin 2014; 10:389-398.
11. Borlaug BA, Lam CS, Roger VL, et al. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009; 54:410-418.
12. Narayanan A, Aurigemma GP, Chinali M, et al. Cardiac mechanics in mild hypertensive heart disease: a speckle-strain imaging study. Circ Cardiovasc Imaging 2009; 2:382-390.
13. Shah AM, Claggett B, Sweitzer NK, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 2015; 132:402-414. This article described the prognostic significance of impaired LV systolic function in HFpEF. Impaired LV longitudinal strain was shown to predict HF hospitalization, cardiovascular death, or aborted cardiac arrest in HFpEF independently of clinical predictors.
14. Rosen BD, Edvardsen T, Lai S, et al. Left ventricular concentric remodeling is associated with decreased global and regional systolic function: the Multiethnic Study of Atherosclerosis. Circulation 2005; 112:984-991.
15. Su G, Cao H, Xu S, Lu Y, et al. Left atrial enlargement in the early stage of hypertensive heart disease: a common but ignored condition. J Clin Hypertens (Greenwich) 2014; 16:192-197.
16. Melenovsky V, Borlaug BA, Rosen B, et al. Cardiovascular features of heart failure with preserved ejection fraction vs. nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007; 49:198-207.
17. Tan YT, Wenzelburger F, Lee E, et al. Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction. Heart 2010; 96:1017-1023.
18. Melenovsky V, Hwang SJ, Redfield MM, et al. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail 2015; 8:295-303. This study showed that HFpEF patients had left atrial (LA) dysfunction as evidenced by increased LA stiffening and greater LA pressure pulsatility compared with hypertensive controls and patients with HFrEF.
19. Santos AB, Kraigher-Krainer E, Gupta DK, et al. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail 2014; 16:1096-1103.
20. Shah AM, Lam CS. Function over form? Assessing the left atrium in heart failure. Eur Heart J 2015; 36:711-714. This editorial provides a great summary of the recent trials that examined the clinical significance of LA function in different stages of HF.
21. Pellicori P, Zhang J, Lukaschuk E, et al. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value. Eur Heart J 2015; 36:733-742.
22. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016; 133:484-492. This is an important longitudinal epidemiological study, which highlighted the important reciprocal association between HF and atrial fibrillation (AF), where AF preceded and followed both HFpEF and HFrEF in Framingham Heart Study participants with new-onset AF and/or HF between 1980-2012.
23. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003; 107:714-720.
24. Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010; 56:845-854.
25. Maréchaux S, Samson R, van Belle E, et al. Vascular and microvascular endothelial function in heart failure with preserved ejection fraction. J Card Fail 2016; 22:3-11. This paper provides the first evidence that microvascular endothelial dysfunction is impaired in HFpEF by demonstrating lower resting endothelial-related microvascular vasomotion and impaired reactive hyperemia in HFpEF compared with hypertensive controls.
26. Lee JF, Barrett-O'Keefe Z, Garten RS, et al. Evidence of microvascular dysfunction in heart failure with preserved ejection fraction. Heart 2016; 102:278-284. This study confirmed the presence of both macrovascular and microvascular endothelial dysfunction in HFpEF and, more importantly, highlighted the dominant role of microvascular over macrovascular endothelial dysfunction in HFpEF.
27. Lam CSP, Lund LH. Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. Heart 2016; 102:257-259.
28. Mohammed SF, Hussain S, Mirzoyev SA, et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015; 131:550-559. This review reported that patients with HFpEF had more coronary microvascular rarefaction and myocardial fibrosis than controls. These changes may contribute to left ventricular diastolic dysfunction and cardiac reserve function impairment.
29. van Empel VPM, Mariani J, Borlaug BA, et al. Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction. J Am Heart Assoc 2014; 3:e001293.
30. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62:263-267.
31. Franssen C, Chen S, Unger A, et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail 2015. [Epub ahead of print]
32. van Heerebeek L, Hamdani N, Falcao-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012; 126:830-839.
33. Falcao-Pires I, Hamdani N, Borbely A, et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation 2011; 124:1151-1159.
34. Fazakas A, Szelenyi Z, Szenasi G, et al. Genetic predisposition in patients with hypertension and normal ejection fraction to oxidative stress. J Am Soc Hypertens 2016; 10:124-132. Single nucleotide polymorphisms (SNPs) of genes encoding enzymes related to oxidative stress were used to calculate a genetic risk score for oxidative stress based on the minor allele frequencies of the SNPs. A high score was associated with diastolic dysfunction in a group of patients with hypertension.
35. Wu Y, Cazorla O, Labeit D, et al. Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol Cell Cardiol 2000; 32:2151-2162.
36. Borbely A, Papp Z, Edes I, et al. Molecular determinants of heart failure with normal left ventricular ejection fraction. Pharmacol Rep 2009; 61: 139-145.
37. Zile MR, Baicu CF, Iknomidis JS, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 2015; 131:1247-1259. This studylooked at three groupsof patients: control, hypertension withoutHFpEFand hypertension with HFpEF. Experiments found that only the last group had an increase in passive myocardial stiffness: collagen-dependent and titin-dependent stiffness.
38. Borbely A, van der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005; 111:774-781.
39. López B, Ravassa S, Gonzalez A, et al. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol 2016; 67:251-260. The increase in myocardial CCL is associated with an increase in hospitalization for heart failure in patients with hypertension and heart failure.
40. Ferrari R, Böhm M, Cleland JG, et al. Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail 2015; 17:665-671. This is a great review that summarizes the uncertainties and dilemmas surrounding the pathophysiology of HFpEF, and outlines the previous and upcoming trials in HFpEF.
41. Kelly JP, Mentz RJ, Mebazaa A, et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol 2015; 65:1668-1682.
42. Komajda M, Lam CS. Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 2014; 35:1022-1032.
43. Lim SL, Lam CS, Segers VF, et al. Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. Eur Heart J 2015; 36:2050-2060. This review paper provides a comprehensive update on the role of endotheliumrelated signaling pathways in the development of HF and the potential pathophysiological targets for new HF therapies.
44. Hummel SL, Seymour EM, Brook RD, et al. Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ Heart Fail 2013; 6:1165-1171.
45. Mathew AV, Seymour EM, Byun J, et al. Altered metabolic profile with sodiumrestricted dietary approaches to stop hypertension diet in hypertensive heart failure with preserved ejection fraction. J Card Fail 2015; 21:963-967.
46. Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2016; 315:36-46.